Table 2.
Summary of treatments
| Case | Reason of IC | IC regimen | Total cycle of IC | Cycle of IC with Nivo | Procedure | Operation time (min) | Blood loss (ml) | AC regimen | Cycle of AC | irAE |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Tumor contact to pancreas | FOLFOX + Nivo | 4 | 3 | LDG | 465 | 150 | SOX | 1 | HYPOTHYROIDISM |
| 2 | Lymph contact to pancreas | SOX + Nivo | 3 | 2 | LTG | 424 | 75 | SOX | 5 | no |
| 3 | Lymph contact to liver | SOX + Nivo | 3 | 2 | DG | 289 | 245 | non-AC | – | no |
| 4 | Tumor contact to liver | SOX + Nivo | 5 | 2 | LDG + Partial hepatectomy | 362 | 40 | SOX | 2 | Adrenal insufficiency |
| 5 | Tumor contact to pancreas | SOX + Nivo | 4 | 2 | RDG | 273 | 5 | not yet | – | no |
IC induction chemotherapy, FOLFOX folinic acid, fluorouracil, and oxaliplatin, SOX S-1 and oxaliplatin, Nivo, nivolumab, LDG laparoscopic distal gastrectomy, RDG robotic distal gastrectomy, LTG laparoscopic total gastrectomy, AC adjuvant chemotherapy, irAE immune-related adverse events